Announcements

This section will provide you the latest announcements from Galderma (UK) Ltd.  For international Press Releases visit the international galderma.com website.

March - 2016 - Restylane Introduces the world's most extensive aesthetic treatment range


Lausanne, Switzerland March 31st, 2016.  Galderma, the leading global dermatology company, announced today the further extension of the Restylane brand range. Following the integration of the Emervel range of Hyaluronic Acid fillers, new brand names and packaging, the company now offers the world’s broadest dermal filler range available on the market. The new Restylane products will be launched worldwide this year, starting with the European markets in late Spring.

 Read full announcement Visit restylane.co.uk   Visit aesthetics.galderma.co.uk

 


 

August - 2015 - Galderma launches Cetaphil moisturising body mousse


Watford, United Kingdom.  Galderma launches new innovative Cetaphil body mousse for skin that feels smooth, soothed and conditioned.

 Read full announcement Visit cetaphil.co.uk

 


 

July - 2015 - Galderma launches treatment for the treatment of inflammatory lesions of rosacea (papulopustular) in adult patients.


Watford, United Kingdom.  Galderma launches Soolantra (1% ivermectin cream) indicated for the treatment of inflammatory lesions of rosacea (papulopustular) in adult patients.

 


 

June - 2015 - Galderma launches new corporate logo


Watford, United Kingdom. Galderma is proud to announce the launch of a new corporate logo unveiled at the World Congress of Dermatology 2015 in Vancouver.

 


 

May 2015 - Proof In Real Life - Reveal Event. Sharon Stone heads the launch of Galderma's Campaign to demonstrate natural looking results of aesthetic treatments in real life.

Berlin, Germany. Galderma challenges misconceptions that aesthetic treatments create extreme results by proving the subtle results in real life.  Ten sets of identical twins participated, with one sibling from each pair undergoing treatments with Restylane fillers and/or Restylane Skinboosters.

Read full announcement Visit ProofIRL.com/uk

 


 

March 2015 - Sharon Stone partners with Galderma in a global campaign to prove natural-looking results of aesthetic treatments in real life

Monaco.  The beauty industry is famous for showing extreme looks and altered images. It can be hard to trust results of aesthetic treatments just by looking at an image. We, at Galderma, have decided to put Restylane fillers and Restylane Skinboosters to the test and prove natural-looking results in real life.

Read full announcement Visit ProofIRL.com/uk

October 2014 - Galderma launches SKINPACT Programme in partnership with the International League of Dermatological Societies

Lausanne, Switzerland, 9 October 2014 Galderma is proud to announce the launch of a new global initiative under the SKINPACT Programme that will provide support for two new projects in the field of community dermatology.

Read more at galderma.com

October 2014 - Galderma (UK) Ltd launches CalmuridPro® 

Watford, United Kingdom.  Galderma UK is pleased to announce the launch of CALMURID® PRO, a skin care range containing clinically proven active ingredients for frequent and daily care of dry and damaged skin.

Read full announcement

June 2014 - The New Award Winning Restylane® Skinboosters™ SmartClick™ Delivery System

Watford, United Kingdom.  Galderma prides itself on working hand in hand with physicians to offer the best solutions and products to help achieve the goals of patients, and as a testament to this we are pleased to share with you news that the new Restylane® Skinboosters™ SmartClick™ delivery system has won the Red Dot Award for High Design Quality 2014.

Read full announcement

May 2014 - Actinica Lotion offers new hope for patients at high risk of non-melanoma skin cancer

Watford, United Kingdom.  Galderma today announced that ACTINICA® Lotion is now available for the prevention of non-melanoma skin cancer (NMSC) in high risk patients, including those who have had an organ transplant, undergone chemotherapy for malignant disease or have HIV/AIDS. It is the first and only medical device to demonstrate effectiveness in the prevention of NMSC.

Read full announcement

April 2014 - Treatment for facial redness associated with rosacea now available in the UK

Mirvaso® (brimonidine) 3 mg/g gel is an alpha-2 adrenergic agonist indicated for the symptomatic treatment of facial erythema of rosacea in adult patients and is now available in the UK.

The active ingredient, brimonidine, restricts excessive blood flow to the upper layers of the skin. The topical gel is applied to the forehead, chin, nose and cheeks, and can reduce facial redness for up to 12 hours. Mirvaso offers a new and effective management option for a commonly misunderstood inflammatory skin condition..

Read full announcement

March 2014 - Restylane reaches milestone with 20 million treatments worldwide

Watford, United Kingdom.  The Restylane range of fillers and skinboosters has been used in over 20 million aesthetic treatments worldwide. With over 30 publications based on controlled trials, Restylane treatments have been trusted for close to two decades by clinics and patients worldwide.

11th February 2014 - Nestlé Skin Health is created targeting global skin health needs

Lausanne, Switzerland.  Today, Nestlé S.A. (Nestlé) announced the creation of Nestlé Skin Health S.A., a global leader focused on meeting the world’s increasing skin health needs with a scientifically-proven broad range of innovative products.  The company will be formed by the acquisition of 50% of Galderma Pharma S.A. (Galderma), subject to regulatory clearance. Galderma was established in 1981 as a dermatology-focused, Swiss-based joint-venture between Nestlé and L’Oréal S.A. (L’Oréal) and had sales of CHF 2.0 billion in calendar year 2013.

Read full announcement

6th June 2013 - Galderma initiates clinical development of novel muscle relaxant

Lausanne, Switzerland. Galderma today announced that it has initiated clinical development of a novel muscle relaxant, based on an advanced formulation of botulinum toxin, with the first cohort of patients already treated in the initial clinical study. “Muscle relaxants are a key medical solution aesthetic physicians can use to create balanced and optimal results for their patients.

We aim to strengthen our portfolio with a new and proprietary muscle relaxant in territories where Galderma does not have access to Azzalure/Dysport, such as North America” commented Humberto C. Antunes, President and CEO of Galderma. “We look forward to rapidly advancing this innovative product in countries where we do not currently promote Azzalure or Dysport in aesthetics.” The first study is expected to be completed in a short period of time, with a second study planned to begin before the end of the year.

According to Medical Insights Inc., a leading independent market research company in aesthetics, the market for muscle relaxants in aesthetics is expected to be $1,211.8 million in 2013 and is projected to exceed $1,588.8 million by 2017 (Published in the Global Aesthetic Market Study, January 2013).

12th December 2014 - Galderma, world's leading company focused exclusively on dermatology, acquires Spirig

Lausanne, Switzerland, Galderma Pharma S.A. (“Galderma”), a global specialty pharmaceutical company focused on dermatology and Spirig Pharma A.G. (“Spirig”), a leading company in the development, production, and marketing of dermatological products, today announced that they have entered into a definitive agreement under which Galderma will acquire Spirig.

25th February 2011 - Galderma declares its offer for Q-Med unconditional and will acquire all tendered shares

Shareholders representing 93.98% have accepted Galderma’s offer

Galderma Pharma S.A., a global innovation-based company focused on providing medical solutions for dermatology patients and physicians, and Galderma Holding AB (together “Galderma”) today announce that all conditions for the completion of its all cash offer to acquire all the shares of Q-Med AB (publ) (“Q-Med”) (the “Offer”) have been fulfilled.  Accordingly, the Offer is declared unconditional in all respects and Galderma will complete the Acquisition of the shares tendered in the Offer.  Settlement is expected to begin on or about 3 March 2011.

13th January 2011 Galderma Launches Emervel hyaluronic acid dermal filler range

Paris (France) and Lausanne (Switzerland), Galderma, a global pharmaceutical  company, today announced the launch of EMERVEL®, a complete range of nine scientifically-advanced and clinically-proven hyaluronic acid dermal fillers. Indicated for the treatment of facial lines, contouring and volume loss, the EMERVEL range of fillers carries the Medical Device CE mark 0459. It is also available with the widely-used local anaesthetic lidocaine. Commercialisation in the UK, France, Germany, Italy, Spain, Brazil and Argentina is scheduled for 2011.

galderma.co.uk is focused on educating the public and patients about skin conditions and the different types of treatments that are available to treat and manage these diseases. This site is not intended as a substitute for medical advice from your doctor, dermatologist, or other healthcare professional and may include discussions about therapies or treatment options that are not suitable for your individual needs. We encourage you to use the information contained in this site to educate yourself about your disease and allow better communication between you and your healthcare professional.  Always consult a dermatologist or a healthcare professional for more information about your condition and the appropriate treatment / product that is right for your individual needs.

Corporate responsibility

Growing a responsible dermatological community

Discover some of the positive initiatives we are involved in across the world

Read

Video

We are committed

See all videos